Soma (carisoprodol) NDC 0037-2001

NDC codes

FDA NDC Directory

Product NDC (as listed)0037-2001Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00037-2001Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0037-2001-01	00037200101	100 TABLET in 1 BOTTLE, PLASTIC (0037-2001-01)Marketed from Nov 1, 1995

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Soma
Generic name (nonproprietary): carisoprodol
Active ingredients: Carisoprodol — 350 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Viatris Specialty LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 011792
Marketing start: Nov 1, 1995
Listing expires: Dec 31, 2026
DEA schedule: CIV
Other FDA classes: Centrally-mediated Muscle Relaxation (Physiologic effect)
Identifiers: Product ID 0037-2001_7272db18-d8cf-4bd0-ab9d-37e191a06f18SPL ID 7272db18-d8cf-4bd0-ab9d-37e191a06f18SPL set ID 6297cf20-830a-11dc-94c8-0002a5d5c51bRxCUI 197446, 213695, 730794, 730918UNII 21925K482H
Pharmacologic class: Muscle Relaxant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400037200101 followed by a unit qualifier and the quantity

Package 00037-2001-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 29, 2025.

Indications (excerpt from the label)

SOMA is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Limitation of Use SOMA should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [ see Dosage and Administration (2) ]. SOMA is a muscle relaxant indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. (1) Limitations of Use • Should only be used for acute treatment periods up to two or three weeks (1)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 011792

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 011792
Product	Strength	Form · route	Labeler	Product NDC
Carisoprodol	Carisoprodol 250 mg/1	TabletOral	Mylan Pharmaceuticals Inc.	51525-5901
Somacarisoprodol	Carisoprodol 250 mg/1	TabletOral	Viatris Specialty LLC	0037-2250